These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 412968)

  • 21. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
    Ganapathi R; Grabowski D; Schmidt H
    Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of tubulin with a new fluorescent analogue of vinblastine.
    Chatterjee SK; Laffray J; Patel P; Ravindra R; Qin Y; Kuehne ME; Bane SL
    Biochemistry; 2002 Nov; 41(47):14010-8. PubMed ID: 12437358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids.
    Todd GC; Griffing WJ; Gibson WR; Morton DM
    Cancer Treat Rep; 1979 Jan; 63(1):35-41. PubMed ID: 105807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro.
    Jordan MA; Himes RH; Wilson L
    Cancer Res; 1985 Jun; 45(6):2741-7. PubMed ID: 3986806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies with 4'-deoxyepivincristine (vinepidine), a semisynthetic vinca alkaloid.
    Mullin K; Houghton PJ; Houghton JA; Horowitz ME
    Biochem Pharmacol; 1985 Jun; 34(11):1975-9. PubMed ID: 4004913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The action of two Vinca alkaloids on B16 melanoma in vitro.
    Donoso JA; Himes RH
    Cancer Biochem Biophys; 1984 Jun; 7(2):133-45. PubMed ID: 6467174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
    Dorr RT; Alberts DS
    J Natl Cancer Inst; 1985 Jan; 74(1):113-20. PubMed ID: 3855472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activities of harringtonine and homoharringtonine, cephalotaxus alkaloids which are active principles from plant by intraperitoneal and oral administration.
    Takeda S; Yajima N; Kitazato K; Unemi N
    J Pharmacobiodyn; 1982 Oct; 5(10):841-7. PubMed ID: 7161711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A randomized controlled study on vindesine and vincristine in combination with prednisolone in the treatment of adult acute lymphocytic leukemia and blastic crisis of chronic myeloid leukemia].
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2500-8. PubMed ID: 6580840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
    Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
    Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vinca-23-oyl amino acid derivatives: as new anticancer agents (review).
    Bhushana Rao KS; Collard MP; Trouet A
    Anticancer Res; 1985; 5(4):379-86. PubMed ID: 3898995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of deacetyl vinblastine amide sulfate (vindesine) in rodents and mitotic accumulation studies in culture.
    Sweeney MJ; Boder GB; Cullinan GJ; Culp HW; Daniels WD; Dyke RW; Gerzon K; McMahon RE; Nelson RL; Poore GA; Todd GC
    Cancer Res; 1978 Sep; 38(9):2886-91. PubMed ID: 679195
    [No Abstract]   [Full Text] [Related]  

  • 33. Determination of tissue concentrations of vinca alkaloids by radioimmunoassay.
    Owellen RJ; Blair M; Van Tosh A; Hains FC
    Cancer Treat Rep; 1981; 65(5-6):469-75. PubMed ID: 7237468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modification of Catharanthus roseus alkaloids: a lactone derived from 17-deacetylvinblastine.
    De Bruyn A; Verzele M; Dejonghe JP; Bhushana Rao KS; Collard MP; Trouet A; Hannart J
    Planta Med; 1989 Aug; 55(4):364-6. PubMed ID: 2813571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vinblastine and vincristine--growth-inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells.
    Gout PW; Noble RL; Bruchovsky N; Beer CT
    Int J Cancer; 1984 Aug; 34(2):245-8. PubMed ID: 6469399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
    Houghton JA; Williams LG; Torrance PM; Houghton PJ
    Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).
    Dyke RW; Nelson RL
    Cancer Treat Rev; 1977 Jun; 4(2):135-42. PubMed ID: 329987
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells.
    Howard SM; Theologides A; Sheppard JR
    Cancer Res; 1980 Aug; 40(8 Pt 1):2695-700. PubMed ID: 6248211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.
    Zhou XJ; Martin M; Placidi M; Cano JP; Rahmani R
    Eur J Drug Metab Pharmacokinet; 1990; 15(4):323-32. PubMed ID: 2088769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological properties of a new alpha-aminophosphonic acid derivative of vinblastine.
    Pierré A; Lavielle G; Hautefaye P; Seurre G; Leonce S; Saint-Dizier D; Boutin JA; Cudennec CA
    Anticancer Res; 1990; 10(1):139-44. PubMed ID: 2334119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.